A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis,
No takes yet. Share an insight, caveat, or question.
John H. Noseworthy (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: